BJMO - volume 6, issue 6, december 2012
J-F. Baurain MD, PhD, P. Manlow , F. Cornélis MD
The incidence of melanoma has increased continuously these last decades. Fortunately, cure is possible in most cases thanks to diagnosis at an early stage. Nevertheless, in some instances, melanoma is diagnosed at later stages and in other cases relapses occur. Moreover, melanoma is the deadliest cutaneous cancer and more importantly the most common origin of death due to cancer in young people. Thankfully though, hope for these patients has been increasing during the past three decades with the increased insight in the underlying oncogenic mutations. This progress has opened up new perspectives for etiological targeted therapies. This review will focus on the recent advances in melanoma treatment. (BELG J MED ONCOL 2012;6:194–200)
Read moreBJMO - volume 6, issue 4, september 2012
J-F. Baurain MD, PhD, W. Lybaert MD
It has become a tradition to hold the biennial International Conference on Thrombosis and Haemostasis Issues in Cancer (ICTHIC) in Bergamo. Bergamo is a quiet town in Northern Italy located on a hilltop beyond the Alps. Over 700 physicians with different backgrounds but the same interest attended the meeting this year from April 20th to April 22nd. The meeting provides a unique opportunity for reviewing the different molecular and clinical findings on thrombosis and haemostasis issues in cancer and for updating the guidelines on prophylaxis and treatment of Venous Thrombo-Embolic Events (VTE) in cancer patients. This congress report covers several key topics: duration of prophylaxis in cancer patients undergoing surgery, prevention in medical cancer patients, type and duration of VTE treatment in cancer patients, place of the newer anti-thrombotic agents in cancer patients and survival advantage of Low-Weight Molecular Heparins (LWMH). (BELG J MED ONCOL 2012;6:140–143)
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
